Prescription Drug Promotion from 2001-2014: Data from the US Food and Drug Administration

被引:11
|
作者
Sullivan, Helen W. [1 ]
Aikin, Kathryn J. [1 ]
Chung-Davies, Eunice [1 ]
Wade, Michael [1 ]
机构
[1] US FDA, Silver Spring, MD USA
来源
PLOS ONE | 2016年 / 11卷 / 05期
关键词
CONSUMER; TELEVISION; EXPOSURE;
D O I
10.1371/journal.pone.0155035
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The volume of prescription drug promotion over time is often measured by assessing changes in ad spending. However, this method obscures the fact that some types of advertising are more expensive than others. Another way to measure the changes in prescription drug promotion over time is to assess the number of promotional pieces submitted to the U.S. Food and Drug Administration (FDA). Form FDA 2253 collects information such as the date submitted and the type of material submitted. We analyzed data from Forms FDA 2253 received from 2001-2014. We examined the frequency of submissions by audience (consumer and healthcare professional) and type of promotional material. There was a noted increase in prescription drug promotion submissions across all media in the early 2000s. Although non-Internet promotion submissions have since plateaued, Internet promotion continued to increase. These results can help public health advocates and regulators focus attention and resources.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Prescription Drug Advertising and Promotion: Learnings from Recent Food and Drug Administration Warning Letters
    Eric B. Benson
    Sherman N. Alfors
    Drug information journal : DIJ / Drug Information Association, 2007, 41 : 281 - 289
  • [2] Prescription drug advertising and promotion: Learnings from recent food and drug administration warning letters
    Benson, Eric B.
    Alfors, Sherman N.
    DRUG INFORMATION JOURNAL, 2007, 41 (03): : 281 - 289
  • [3] Prescription medications for use in pregnancyeperspective from the US Food and Drug Administration
    Ren, Zhaoxia
    Bremer, Andrew A.
    Pawlyk, Aaron C.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 225 (01) : 33 - 42
  • [4] Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014
    Rathi, Vinay K.
    Wang, Bo
    Ross, Joseph S.
    Downing, Nicholas S.
    Kesselheim, Aaron S.
    Gray, Stacey T.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2017, 156 (04) : 683 - 692
  • [5] LONGITUDINAL TRENDS IN US DRUG SHORTAGES FOR MEDICATIONS USED IN CRITICAL CARE (2001-2014)
    Umar, Suleman
    Goyal, Munish
    Fox, Erin
    Zocchi, Mark
    Pines, Jesse
    Hawley, Kristy
    Mazer-Amirshahi, Maryann
    CRITICAL CARE MEDICINE, 2015, 43 (12)
  • [6] Longitudinal Trends in US Drug Shortages for Medications Used in Emergency Departments (2001-2014)
    Hawley, Kristy L.
    Mazer-Amirshahi, Maryann
    Zocchi, Mark S.
    Fox, Erin R.
    Pines, Jesse M.
    ACADEMIC EMERGENCY MEDICINE, 2016, 23 (01) : 63 - 69
  • [7] How the US Food and Drug Administration Can Solve the Prescription Drug Shortage Problem
    Schweitzer, Stuart O.
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2013, 103 (05) : E10 - E14
  • [8] Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration
    Dodson, Andrew
    Mi, Kevin
    Russo, Daniel P.
    Scott, Christina
    Saulnier, Muriel
    Snyder, Kevin
    Racz, Rebecca
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2021, 111
  • [9] US food and drug administration
    Goodman, Jesse
    ONCOLOGY-NEW YORK, 2006, 20 (08): : 946 - 946
  • [10] US Food and Drug Administration
    Blumenthal, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S37 - S37